Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1000 SPRING ST SILVER SPRING MD 20910 |
Tel: | N/A |
Website: | https://www.unither.com |
IR: | See website |
Key People | ||
Martine A. Rothblatt Chairman of the Board, Chief Executive Officer | Michael Benkowitz President, Chief Operating Officer | James C. Edgemond Chief Financial Officer, Treasurer | Paul A. Mahon Executive Vice President, General Counsel, Corporate Secretary |
Business Overview |
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind's Afrezza (insulin human) Inhalation Powder. |
Financial Overview |
For the fiscal year ended 31 December 2023, United Therapeutics Corporation revenues increased 20% to $2.33B. Net income increased 35% to $984.8M. Revenues reflect Orenitram segment increase of 11% to $359.4M, Unituxin segment increase of 9% to $198.9M, United States segment increase of 21% to $2.2B, Rest of World segment increase of 3% to $125.3M. Net income benefited from Interest Income increase from $45.2M to $162.7M (income). |
Employees: | 1,168 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8,740M as of Dec 31, 2023 |
Annual revenue (TTM): | $2,328M as of Dec 31, 2023 |
EBITDA (TTM): | $1,242M as of Dec 31, 2023 |
Net annual income (TTM): | $984.80M as of Dec 31, 2023 |
Free cash flow (TTM): | $747.60M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 47,058,545 as of Feb 14, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |